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ABSTRACT (160/200) 
Identifying new causes of permanent neonatal diabetes (diagnosis <6 months; PNDM) 
provides important insights into -cell biology. Patients with Down syndrome (DS) resulting 
from trisomy 21 are 4 times more likely to have childhood diabetes with an intermediate 
HLA association. It is not known if DS can cause PNDM. We found trisomy 21 was 7 times 
more likely in our PNDM cohort than in the population (13/1522 = 85/10,000 observed vs. 
12.6/10,000 expected) and none of the 13 DS-PNDM cases had a mutation in the known 
PNDM genes which explained 82.9% of non-DS PNDM. Islet autoantibodies were present in 
4/9 DS-PNDM patients but DS-PNDM was not associated with polygenic susceptibility to 
type 1 diabetes. We conclude that trisomy 21 is a cause of autoimmune PNDM that is not 
HLA associated. We propose that autoimmune diabetes in DS is heterogeneous and includes 
coincidental type 1 diabetes that is HLA associated and diabetes caused by trisomy 21 that is 
not HLA associated.  
Permanent neonatal diabetes (PNDM) is diagnosed before the age of 6 months and a genetic 
diagnosis is possible for >82% of cases (1). Twenty-four causative PNDM genes have been 
identified (1–4) and 4 of these cause monogenic autoimmune PNDM that results from 
destruction of the β-cells very early in life (FOXP3, IL2RA, LRBA and STAT3). Identifying 
novel causes of autoimmune neonatal diabetes can provide key insights into the development 
of autoimmunity and can provide new targets for therapeutic intervention.   
Down syndrome (DS) is caused by trisomy of chromosome 21 and has an incidence of 1:700 
to 1:1100 live births (5). Large studies have shown childhood-onset autoimmune diabetes is 4 
times more common in DS than in the general population, and has an intermediate HLA 
association (6). There have been three reported cases of DS with diabetes diagnosed before 6 
months (7,8). However, it is not known whether DS was the cause of PNDM (DS-PNDM) or 
a coincidental finding in these patients. The aim of our study was to use our large 
international cohort of PNDM patients to assess whether DS can aetiologically cause PNDM. 
We assessed clinical phenotype, islet autoantibodies, and polygenic risk of T1D in patients 
with monogenic PNDM and DS-PNDM. 
 
METHODS: 
STUDY POPULATION 
We defined permanent neonatal diabetes (PNDM) as diabetes diagnosed before the age of 6 
months which is treated with continual insulin treatment. We studied 1522 DNA samples 
from two international collections of PNDM patients, 1360 recruited in Exeter and 162 
recruited in Chicago. These either had a confirmed monogenic aetiology (82.9%, n=1262) or 
had been tested (and were negative) for all 24 known genes (17.1%, n=260). Clinical 
information was provided by the referring physician via a comprehensive referral form. This 
includes a section for the reporting of extra pancreatic clinical features.  
GENETIC TESTING 
Testing of the known genes 
All individuals diagnosed in the first 6 months of life were tested for mutations either by 
rapid Sanger sequencing of ABCC8, KCNJ11 and INS or if no mutation was identified via 
targeted DNA sequencing through next generation sequencing (tNGS) of all 24 genes (1–
4,9). This assay can detect single nucleotide variants, insertion-deletions, copy number 
variation and structural variation (9). 
Exclusion of Trisomy 21 
We used SavvyCNV (10,11) to screen for trisomy 21 in the PNDM and autoimmune-PNDM 
cohorts where tNGS was undertaken (n=445). This uses off-target reads from tNGS data to 
detect large copy number and structural variants. 
Type 1 Diabetes Genetic Risk Score 
The T1D genetic risk score was generated where there was sufficient DNA as previously 
described (12). Briefly, we genotyped single nucleotide polymorphisms (SNPs) tagging the 
top 10 risk alleles for T1D and summed their log transformed odds ratios before dividing by 
the total number of alleles to obtain a numeric score. None of the SNPs used are on 
chromosome 21. We used T1D-GRS from 1963 gold-standard T1D individuals (all diagnosed 
<17 years) from the Wellcome Trust Case Control Consortium as a representative samples 
for polygenic T1D (13). As part of the score generation, SNPs rs2187668 and rs7454108 
were used to tag DR3 (DRB1*0301-DQA1*0501-DQB1*0201) and DR4-DQ8 (DRB1*04-
DQA1*0301-DQB1*0302) alleles. These SNPs have been shown to be 98.6% sensitive and 
99.7% specific for tagging DR3/DQ4-DQ8 (14). We used rs3129889 to tag HLA DRB1*15 
(15). 
The T1D genetic risk score (T1D-GRS) was available for 13 patients with DS-PNDM, 458 
individuals with a confirmed non-autoimmune monogenic aetiology (non-DS PNDM) and 40 
individuals with a monogenic cause of autoimmune PNDM (autoimmune non-DS PNDM). 
There was no difference in clinical features between individuals with or without T1D-GRS. 
ISLET AUTOANTIBODY TESTING 
Islet autoantibodies GADA, IA-2A and/or ZnT8A were measured either by local assays or 
from plasma on the sample received at the Exeter Clinical Laboratory using an automated 
ELISA based assay as previously described (16). We used >97.5th centile of controls 
(n=1559) to define positivity for autoantibodies.  
STATISTICAL ANALYSIS 
The Mann-Whitney U and Kruskal-Wallis tests were used to compare continuous variables 
and the Fisher’s exact test was used to compare categorical variables. Statistical analysis was 
undertaken in Stata14 (StataCorp, College Station, USA). 
ETHICAL APPROVAL 
This study was approved by the Genetic Beta Cell Research bank, Exeter, UK and the 
University of Chicago, Chicago, IL, USA. Ethical approval was provided by the North Wales 
Research Ethics Committee, UK (IRAS project ID 231760) and the University of Chicago 
Institutional Review Board (IRB #6858, 15617B).  
RESULTS: 
Trisomy 21 is enriched in PNDM. To assess whether DS is enriched in our PNDM cohort, 
we compared the observed frequency in the PNDM cohort to the expected frequency based 
on the population prevalence. Using clinical data obtained at referral we identified 13/1522 
(0.9%) individuals with DS-PNDM in our international PNDM cohort. In all 13 individuals 
trisomy 21 was confirmed by karyotyping and analysis of tNGS data using SavvyCNV. We 
did not detect Trisomy 21 in any individual without a clinical diagnosis of Down syndrome. 
The observed frequency in our cohort was therefore 85/10,000 (95% CI 45-146), 6.7 fold 
higher than the expected population frequency of 12.6/10,000 (95% CI 12.4-12.8) (P=0.007) 
(Fig. 1) (5). 
Patients with DS-PNDM do not have mutations in any of the 24 genes known to causes 
monogenic PNDM. We next assessed the presence of known monogenic aetiology in 
patients with DS-PNDM. None of the 13 DS-PNDM individuals had pathogenic variants in 
the 24 known PNDM genes. In contrast, 1262 of 1522 (82.9%) of the non-DS PNDM had a 
monogenic aetiology (Fig. 2; P=1.4 x 10-10). Taken together, these two results strongly 
support trisomy 21 as a cause of PNDM. 
Islet autoimmunity is common in DS-PNDM. To further assess the underlying aetiology of 
DS-PNDM, we compared the clinical characteristics of the DS-PNDM patients with the 
PNDM cohort with a non-autoimmune monogenic cause (non-DS PNDM; n=458) or 
monogenic autoimmunity (autoimmune non-DS PNDM; n=40). We found that 44% (4/9) of 
the DS-PNDM individuals were positive for one autoantibody (all GADA; none IA2A or 
ZnT8A) with time from diabetes diagnosis to testing ranging from 4 months to 10 years ( 
Table 1). This was similar to the autoimmune non-DS PNDM (46%, 13/28, P=1.0) but higher 
than the non-DS PNDM (21/293, 7%, P=0.004) (Table 2).  This supports an autoimmune 
aetiology in DS-PNDM.  
The median age of onset of diabetes was similar in all three groups (Table 2). The 
birthweight of the DS-PNDM cohort was low (-1.23 SDs). This was similar to the non-DS 
PNDM individuals (-1.74 SDs, P=0.87) and lower than those with autoimmune non-DS 
PNDM (-0.39 SDs, P=0.02). Full clinical information for each subject with DS-PNDM and 
diabetes is given in table 1. 
DS-PNDM is genetically distinct from Type 1 diabetes. To further investigate the 
aetiology of autoimmune diabetes in DS-PNDM we assessed polygenic risk for T1D (T1D-
GRS) in DS-PNDM and compared it to both T1D and monogenic PNDM. T1D-GRS in 
individuals with DS-PNDM was similar to non-diabetic controls (Fig. 3, median T1D-GRS 
0.61 vs 0.55, P= 0.33), non-DS PNDM (0.61 v 0.55, P=0.48) and autoimmune non-DS 
PNDM (0.61 v 0.57, P=0.65) but lower than the T1D control group (0.61 v 0.69, P=0.0001). 
While 10/13 individuals with DS-PNDM carried a copy of either DR3 or DR4, none had the 
highest risk HLA DR3/DR4 genotype compared to 34% (666/1963) of T1D controls 
(P=0.006; Table 1). Furthermore, 4/13(36%) DS-PNDM cases carried the HLA DRB1*15 
allele which is dominantly protective against T1D compared to 2% (40/1963) of T1D 
controls (P=0.0001). This is similar to non-diabetic controls who carry the protective HLA 
DRB1*15 allele (1643/2938, P=0.27). These data suggest that DS-PNDM is not HLA 
associated and is therefore unlikely to be very-early onset polygenic T1D. 
  
DISCUSSION: 
Our study identifies trisomy 21 as a rare cause of autoimmune PNDM. We have shown that 
DS is 7-fold enriched in our PNDM cohort and none of the DS-PNDM individuals have a 
mutation in any of the 24 known PNDM genes. The antibody data supports an autoimmune 
aetiology in DS-PNDM that is not associated with increased polygenic susceptibility to T1D. 
DS-PNDM is rare within people with DS suggesting that trisomy 21 is a low penetrance 
cause of PNDM.  
We found that PNDM caused by trisomy 21 can be linked to beta-cell autoimmunity as 
shown by the presence of islet antibodies in 4/9 cases (17). Islet antibodies are seen in HLA 
associated T1D and also in autoimmune non-DS PNDM which is not HLA associated (12). 
The proportion of patients with DS-PNDM that were autoantibody positive was similar to 
non-DS PNDM caused by monogenic autoimmunity. The islet antibodies are unlikely to due 
to maternal transfer of antibodies as of the 3 of the 4 GADA positive patients were measured 
after 9 months (18,19). 
Our data suggest prenatal onset of beta cell dysfunction/destruction in DS-PNDM. We found 
that the birthweight of the DS-PNDM individuals was reduced (median z-score -1.23); this is 
lower than the birth weight seen in DS without PNDM (z-score boys: -0.47 girls: -0.07).  
Interestingly, the birthweight was similar to non-DS-PNDM patients whose lower 
birthweight is due to reduced insulin secretion in utero. Global immunological changes in 
individuals with DS have been identified including defects in T-cell regulation and thymus 
development that are evident in new-borns (20). These data taken together suggest prenatal 
onset of autoimmunity and pancreatic dysfunction.  
We found that individuals with DS-PNDM do not have increased polygenic risk of T1D even 
though they develop diabetes before 6 months of age. This is contrary to T1D in which the 
HLA association is increased with younger age of diagnosis (21). Furthermore, 4/13 (31%) 
individuals carry the DRB1*15 haplotype which provides dominant protection against T1D 
and is very rarely seen in patients with T1D (40/1963; 2%). Two of these also carried DR3 or 
DR4, however inheritance with the DRB1*15 allele nullifies the risk allele (22). The DS-
PNDM cohort is of mixed ethnicities (6 Caucasian, 3 Middle Eastern, 3 Hispanic, 1 mixed), 
however population stratification does not account for the difference in HLA alleles between 
DS-PNDM cases and T1D; the HLA DR3/DR4 diplotype is strongly predisposing and the 
DRB1*15 allele is strongly protective for T1D across these populations(23–25). These data 
support that DS-PNDM is not HLA associated. 
A previous study showed that DS with diabetes had intermediate HLA association (7). The 
highest risk HLA diplotype - DR3/DR4 – was present in half as many DS diabetes cases 
compared to T1D (17% of DS diabetes, 38% of T1D, 3% of controls). We propose that this is 
explained by diabetes in DS in these studies reflecting a mixture of 2 subtypes of 
autoimmune diabetes, one caused by trisomy 21 related immune (not HLA associated) and 
the other is coincidental HLA associated polygenic T1D in which the trisomy 21 related 
immune dysregulation may not be playing as strong a role. A mixture of two aetiologies is 
also reflected by the observation that age of onset of diabetes in DS is biphasic, with a peak at 
one year and another at 10 years of age, the latter coinciding with non-DS T1D. 
We have shown a 7 fold increase in the prevalence of diabetes before the age of 6 months in 
DS. Previous authors (6) have shown an increase of diabetes between 0.5-18 years of 
approximately 4 fold. The difference in prevalence means patients are far less likely to get 
diabetes before 6 months (7/100,000) compared to 0.5 -18 years (700/100,000). 
A complex interaction between multiple genes on chromosome 21 may be responsible for 
autoimmunity in DS. The autoimmune regulator gene, AIRE , which is in the minimal region 
for DS on chromosome 21, regulates the ectopic expression of tissue restricted antigens in the 
thymus to expose developing T cells to self-peptides; those that are strongly reactive are 
removed or reprogrammed (26). Mutations in AIRE cause Autoimmune Polyendocrine 
Syndrome Type 1 which commonly includes endocrine autoimmunity (27). AIRE has been 
shown to be aberrantly expressed in individuals with DS. A study of infant (0-6 months) 
thymus’ removed during cardiac surgery found that AIRE mRNA and protein expression was 
elevated in DS cases (n=5) vs non-DS controls (n=5) (28). The mRNA expression of two 
genes under AIRE’s control in medullary thymocytes, INS (encoding insulin) and CHRNA1 
(encoding a subunit of muscle acetylcholine receptor) was also increased. Furthermore, this 
study found an increased overall number of medullary thymocytes expressing AIRE, which 
the authors propose could be linked to an effect on thymocyte turnover; AIRE is known to 
promote terminal differentiation in medullary thymocytes (29,30). AIRE has multiple 
complex roles in thymic function (including Treg selection, antigen expression, cell 
differentiation, antigen presentation and chemokine production (31)) and increased 
expression of AIRE was counterintuitively postulated to result in an alteration of the balance 
of these processes and therefore impaired thymic selection and reduced central tolerance 
resulting in increased autoimmunity.  
Two larger larger studies of the DS thymus found that AIRE mRNA expression was reduced 
2-fold in DS thymus’, and that genes under AIRE’s control in medullary thymocytes had 
reduced expression (32,33). They found that the number of medullary thymocytes positive for 
AIRE was also reduced. Intriguingly, Gimenez-Barcons et al. found that all 3 copies of AIRE 
present in DS cases were equally expressed, albeit at reduced total levels, suggesting 
overcompensation by transcriptional repression of all alleles. The patients in these studies 
were older than those in the study by Skogberg et al. (2 months – 12 years), therefore a 
potential temporal relationship of AIRE expression in DS thymus, possibly linked to AIREs 
role in differentiation and turnover of thymocytes (29,30), could explain the difference. None 
of the cases were reported to have diabetes; however 11/19 reported by Gimenez-Barcons et 
al. had organ specific autoimmunity (hypothyroidism, Graves disease or celiac disease).  
Additional genes contained in chromosome 21 have been linked to the increased incidence of 
autoimmune diabetes in DS. The UBASH3A gene, also on chromosome 21, has been 
associated (and the association replicated) with type 1 diabetes and has a role in the 
regulation of T-cells (34). UBASH3A down-regulates t-cell receptor induced NFкB signalling 
(35). NFкB signalling regulates multiple aspects of the innate and adaptive immune system 
including the expression of IL2 (36), a pleiotropic cytokine whose roles include the 
regulation of self-tolerance (37). Furthermore, a gene cluster containing four interferon 
receptors (IFNAR1, IFNAR2, IFNGR2, and IL10RB) is on chromosome 21 and it has been 
shown that increased interferon signalling is a hallmark of DS (38). RNA-sequencing 
experiments showed that interferon-related factors were consistently overexpressed in DS 
lymphocytes compared to controls.  Increased interferon signalling has been implicated in 
multiple autoimmune diseases, including T1D (39–42).  
To our knowledge this is the largest study of DS-PNDM. Study of additional individuals will 
provide further insight into the underlying mechanism of DS-PNDM. An interesting follow 
up would be to assess the T1D-GRS in an older cohort of DS individuals with diabetes to 
assess if genetic risk for T1D increases with older age at onset. Furthermore, we were unable 
to test all islet autoantibodies in all individuals near to diagnosis or perform 
immunophenotyping on their leukocytes. This would provide further understanding of the 
autoimmunity in DS-PNDM.  
In conclusion, we have shown that trisomy 21 is a cause of PNDM. The underlying 
mechanism of the diabetes is likely to be due to autoimmunity against the beta cells. We 
propose that diabetes in DS is heterogeneous and consists of a subgroup diagnosed very 
young (including PNDM) which is autoimmune but not HLA mediated and a second group 
that is similar to T1D in the non-DS population and has a strong HLA association. Extended 
genetic testing of known monogenic diabetes genes for individuals with DS-PNDM beyond 
the most common forms – activating mutations in ABCC8 or KCNJ11 – may not be needed. 
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FIGURE LEGENDS 
Figure 1 – Down syndrome is enriched in our PNDM cohort. DS has a population 
prevalence of 12.6/10,000 (95% CI 12.4-12.8), whereas in our cohort of 1522 patients with 
neonatal diabetes we have 13 cases, equivalent to 85/10,000 (40.4-144.3); P=0.007). 
Figure 2 – DS-PNDM is not caused by other known neonatal diabetes genes. The 24 
known neonatal diabetes genes account for 82.9% of cases while none of the 13 DS-PNDM 
cases had a mutation in a known gene (P=1.4 x 10-10). 
Figure 3: the T1D-GRS in DS-PNDM. Patients with DS-PNDM (n=13) had a lower score 
than T1D controls (n=1963), and their scores were similar to those with the known 
monogenic forms of non-DS PNDM and autoimmune non-DS PNDM (n=458 and n=40; 
P=0.52) and non-diabetic controls (n=2938, P=0.33). The central line within the box 
represents the median and the upper and lower limits of the box represent the interquartile 
range. The whiskers are the most extreme values within 1.5× the interquartile range from the 
first and second quartiles. 
END OF TEXT OF ARTICLE
Patient Sex Ethnicity Maternal 
age at birth 
Patient 
Current 
age 
Birthweight  
z-scorea 
Age 
diagnosed 
with diabetes 
Treatment HbA1c/% 
(mmol/L)b 
Autoantibodies 
tested 
Autoantibody  
status 
Duration 
diabetes at 
antibody 
testing 
T1D-
GRS  
(centile 
of T1D)c 
HLA DR 
genotyped 
Other conditions 
1 Male Caucasian 
ND 
23 years -0.79 7 weeks Insulin 9.5 (80) 
ND 
 
ND NA 0.37 (0.1) DRB1*15/X Hypothyroidism, ASD 
2 Female 
Hispanic 
 
ND 
 
14 years -3.99 1 week Insulin 8.1 (65) ND ND NA 
0.70 
(53.5) 
DR4/DR4 
Hypothyroidism, hearing 
and vision problems 
3 Male Caucasian 
33y 
1 year -1.02 2 days Insulin ND 
GADA, IA2A, 
ZNT8A 
Negative 1 week 
0.69 
(48.2) 
DR3/DR3 
Tetralogy of Fallot, 
macroglossia 
4 Male Caucasian 
ND 
 
28 years ND 3 months Insulin 8.5 (69) 
GADA, IA2A, 
ZNT8A 
GADA 
positive 
10 years 0.52 (2.5) X/X Seizures 
5 Male Arabic 
37y 
1 year ND 4 months Insulin 8.8 (73) 
GADA, IA2A, 
ZNT8A 
GADA 
positive 
4 months 
0.66 
(33.9) 
DR3/DR3 - 
6 Male Hispanic 
40y 
9 months -2.65 2 weeks Insulin 5.7 (39) 
GADA, IA2A, 
ZNT8A 
Negative 2 months 
0.64 
(25.4) 
DR4/X 
Subclinical 
hypothyroidism, 
macroglossia, 
cardiac malformation 
7 Male 
Mixed (East 
Asian/Caucasian) 
43y 
20 years 0.80 3 days Insulin 8.8 (73) GADA 
GADA 
positive 
8 years 
0.63 
(20.6) 
DR3/X 
Hypothyroidism, coeliac 
disease exocrine 
insufficiency 
8 Male Arabic 
ND 
9 years -1.23 8 weeks Insulin 9.3 (78) GADA, IA2A, 
GADA 
positive 
5 years 0.37 (0.1) DRB1*15/X Macroglossia 
9 Female Turkish 
ND 
15 years ND 3 weeks Insulin 8.1 (65) GADA, IA2A Negative 
1 day 
 
0.61 
(14.3) 
DR3/X Hypothyroidism 
10 Female Hispanic 
ND Died aged 
7 months 
-3.30 3 days Insulin 6.6 (49) ND ND NA 0.49 (0.9) DR4/DRB1*15 - 
11 Male Caucasian 
35y 
6 years -0.84 1 day Insulin 6.6 (49) 
GADA, IA2A, 
ZNT8A 
Negative 5 months 0.48 (0.8) DR3/DRB1*15 
Transient 
hypothyroidism, 
VSD 
12 Male Caucasian 
ND 
17 years 0.19 18 days Insulin 9.8 (84) ND ND ND 
0.69 
(48.2) 
DR4/X 
Seizures, hypothyroidism, 
frequent infections (low 
IgM), 
hepatic abscess 
13 Male Caucasian 
ND 
1 year -1.85 Birth Insulin 7.0 (53) GADA, ZnT8A Negative ND 
0.68 
(44.5) 
DR4/DR4 
Hyperthyroidism, bowel 
obstruction, 
speech and vision 
problems 
 
Table 1: Features of the Down syndrome associated neonatal diabetes cohort. ND – no data. a – z-score adjusted for sex and gestational age. b – latest HbA1c reported by 
clinician. c – Type 1 diabetes genetic risk score based on top 10 risk alleles; centile of T1D refers to the centile of the type 1 diabetes control population that this score 
corresponds with. d – ‘X’ denotes any HLA-DR haplotype other than DR3, DR4 or DRB1*15.  ASD – atrial septal defect. VSD – ventral septal defect
Characteristic   
DS-PNDM 
n=13 
Non-DS PNDM 
n=458 
Autoimmune  
non-DS PNDM 
n=40 
Age diagnosis diabetes  
(weeks) 
  
2.3 (0.4, 7.5) 7 (3, 12) 4 (1, 13.5) 
Female % 
  
23% (3/13) 43% (197/458) 12.5% (5/40)* 
Birthweight z-score† 
  -1.23 (-2.65, -0.84) 
[n=10] 
-1.74 (-2.55, -0.82) 
[n=378] 
-0.39 (-1.06, 0.29)‡ 
[n=30] 
>1 Autoantibody positive§ 
  
4/9 (44%) 21/293 (7%) || 13/28 (46%) 
T1D-GRS¶ 
  
0.61 (0.49-0.66) 0.55 (0.51-0.61) 0.57 (0.52-0.62) 
 
Table 2: Comparison of Down syndrome associated neonatal diabetes (DS-PNDM) with 
monogenic non-autoimmune forms of neonatal diabetes (Non-DS PNDM) and 
monogenic autoimmune neonatal diabetes (autoimmune non-DS PNDM). *Low due to 
males with X-linked IPEX syndrome (n=25/40) †adjusted for sex and gestational age. ‡DS-
PNDM v autoimmune non-DS PNDM P=0.02. §One or more positive titre for GADA, IA2A 
or ZnT8A. ||DS-PNDM v non-DS PNDM P=0.006. ¶Type 1 diabetes genetic risk score; 
centiles based on T1D controls. Age of diabetes diagnosis, birthweight Z-score and T1D-
GRS are given as median with inter-quartile range in parenthesis. Other than where indicated, 
data were similar for all cohorts (P>0.1). 
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